Strategic Merger and Spin-Out Position Investors for Predictable Revenue and High-Growth Innovation!
The biopharmaceutical and technology sectors are undergoing rapid evolution. Investors increasingly seek exposure to companies that combine predictable, recurring revenue with high-growth, innovative pipelines.
Traditional biotech investment carries high clinical and regulatory risk, while technology infrastructure provides tangible asset-backed revenue stability.
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) stands out by bridging these worlds. Through a transformational merger and spin-out strategy, COEP positions investors to benefit from both long-term contracted technology infrastructure revenue and exposure to cutting-edge cell therapy development.
This dual-sector model is a rare opportunity to capture stability and optionality within a single investment ecosystem!
Merger Approved, Biotech Spin-Out Executed
COEP shareholders approved a landmark merger converting the clinical-stage biopharmaceutical company into a dual-sector enterprise. The restructuring anchors $660 million in technology infrastructure operations while distributing $75 million in biotech assets to shareholders as a separate spin-out.
The transaction was executed through three shareholder-approved proposals, including share issuance under the April 2020 merger agreement with Z-Squared Inc., transfer of biotech assets, and a corporate name change from Coeptis Therapeutics Holdings to Z-Squared Inc. Post-merger, Z-Squared shareholders hold 79% of the combined entity, while COEP shareholders retain 21%, along with shares in the standalone biotech entity.
In Simple Words
Coeptis Therapeutics (NASDAQ: COEP) is a company that develops advanced cell therapies to treat cancer, using immune cells that can target tumors in innovative ways.
Recently, COEP completed a big merger that turned the company into two parts: one is a technology infrastructure business worth $660 million that makes steady money from long-term contracts, and the other is a biotech spin-out worth $75 million that keeps the cancer therapy programs. Existing shareholders now own a piece of both, giving them a mix of stable revenue and potential upside from the new cancer treatments.
Technology Infrastructure: The $660M Core Asset
Z-Squared's technology infrastructure operations comprise 9,000 U.S.-based units under multi-year hosting agreements. The model emphasizes capital-intensive physical assets over software subscriptions, delivering high gross margins and long-term revenue visibility. Domestic facility ownership differentiates Z-Squared from competitors dependent on international or third-party capacity.
The company owns and operates physical hardware, negotiates facility hosting agreements, and maintains operational control. This capital-intensive approach trades high gross margins for revenue visibility through multi-year hosting contracts. The domestic facility footprint differentiates Z-Squared from competitors reliant on international data center capacity or third-party hosting.
Cell Therapy Platforms and Strategic NASDAQ Uplisting
The $75 million spin-out houses DVX201 natural killer cell therapy, the SNAP-CAR universal multi-antigen platform from the University of Pittsburgh, and GEAR cell therapy assets developed with VyGen-Bio and the Karolinska Institute.
By maintaining a separate entity, shareholders retain biotech upside while Z-Squared enjoys approximately $100 million in NOLs (tax-loss carryforwards). These tax benefits shield future earnings and support infrastructure expansion or technology development without immediate tax liabilities, enhancing capital efficiency.
Dual-Sector Exposure Optimizes Capital Access
This dual-structure positions COEP to appeal to two distinct investor types: infrastructure-focused institutional investors evaluating long-term hosting contracts and biotech specialists assessing clinical timelines and regulatory milestones.
Leveraging an existing NASDAQ listing avoids traditional IPO costs and complexities, providing streamlined public market access for both entities.
The $835 million combined valuation underscores the potential for operational growth, with infrastructure expansion and biotech development driving future value creation.
Biotech Spin-Out: Innovative Cancer Cell Therapy Platforms
The $75 million spin-out houses Coeptis' leading cell therapy platforms, including:
- DVX201 – an unmodified natural killer (NK) cell therapy from Deverra Therapeutics.
- SNAP-CAR – a universal multi-antigen CAR therapy licensed from the University of Pittsburgh, using antibody adaptors to target tumors with programmable precision.
- GEAR-NK (CD38) – modified NK cells designed to coexist with CD38-targeting monoclonal antibodies, enhancing anti-tumor activity while avoiding immune cell collateral damage.
COEP leverages a novel stem cell expansion platform using cord blood-derived CD34+ cells, producing off-the-shelf NK cells with consistent dosing and scalable manufacturing. These therapies have completed two Phase 1 trials with a proven safety record, avoiding common complications such as graft-versus-host disease or cytokine release syndrome.
Additionally, approximately $100 million in tax-loss carryforwards enhance after-tax cash flow, providing capital for both biotech development and infrastructure expansion without immediate tax liabilities.
COEP's cancer therapies are exciting
Coeptis' cell therapies use natural killer (NK) cells and specialized CAR cells to attack cancer in ways traditional treatments can't. Their therapies are "off-the-shelf," meaning they can be prepared in advance and given to any patient without complex matching.
For example, their GEAR-NK therapy protects the body's NK cells while targeting tumors, making treatments more effective and safer. SNAP-CAR is programmable, so it can be adjusted for different tumor types. This means COEP's therapies could treat more patients, work with existing treatments, and reduce side effects, offering real potential to improve outcomes for people with cancer.
The Bottom Line
In short, COEP gives investors a rare mix of stability and innovation. The technology side provides predictable revenue from long-term contracts, while the biotech spin-out focuses on breakthrough cancer therapies that use natural killer cells and CAR technology to attack tumors in smarter, safer ways.
These therapies could help patients who have few options and represent the next generation of cancer treatment. This merger means shareholders benefit from both steady cash flow and the potential impact of life-changing cancer science.
With the preliminary shareholder approvals completed and operations underway, COEP (now Z-Squared) is positioned to execute its infrastructure expansion and clinical development milestones, creating a compelling long-term potential growth narrative!
